Current treatment options for early HER2-positive breast cancer

04/2020

MUDr. Miloš Holánek

Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno

SUMMARY

Anti-HER2 therapy has long been an integral part of the treatment of patients with HER2-positive breast cancer, which has significantly improved treatment outcomes and disease prognosis. However, despite effective therapy, some patients still relapse. Therefore, other possibilities are being sought to further improve the already very effective therapy.

Key words

anti-HER2 therapy, trastuzumab, pertuzumab, trastuzumab emtansine, neratinib